- Home
- SBRA vs TERN Comparison
SBRA vs TERN Comparison
Compare SBRA & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | TERN |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.8B |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBRA | TERN |
|---|---|---|
| Price | $19.75 | $49.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $21.88 | ★ $48.60 |
| AVG Volume (30 Days) | ★ 2.1M | 1.9M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | ★ 18.52 | 11.81 |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $774,632,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $30.59 | ★ N/A |
| Revenue Growth | ★ 10.15 | N/A |
| 52 Week Low | $15.75 | $1.87 |
| 52 Week High | $21.07 | $50.00 |
Technical Indicators
Market Signals| Indicator | SBRA | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 71.64 |
| Support Level | $18.16 | $38.99 |
| Resistance Level | $20.94 | N/A |
| Average True Range (ATR) | 0.45 | 2.53 |
| MACD | -0.15 | 0.35 |
| Stochastic Oscillator | 16.30 | 89.29 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.